⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

May 23, 2024PharmacoEconomics - OpenOpen Access

Public Health Impact and Cost-Effectiveness Analysis of 4-Component Meningococcal Serotype B Vaccination for Infants in France

Gérard de Pouvourville Manon Breau-Brunel V. Loncle-Provot Ekkehard Beck L. Gaugain Gaëlle Nachbaur C. Pribil

View Full Paper

Ask AI

Bookmark

Share

Abstract

In France, meningococcal serogroup B (MenB) is the most common serogroup causing invasive meningococcal disease (IMD) in infants and young children. Our objective was to illustrate the impact of model choices on health outcomes and the cost-effectiveness of infant vaccination with the multicomponent meningococcal serogroup B vaccine (4CMenB) versus no vaccine in France.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Pouvourville et al. (2024) studied this question.

synapsesocial.com/papers/68e68bf8b6db643587613d24 https://doi.org/10.1007/s41669-024-00488-5

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Cost-Effectiveness of Routine Infant Meningococcal B Vaccination in the NetherlandsOriginal Research · 2026
2Real-world effectiveness and impact of the 4CMenB vaccine against serogroup B invasive meningococcal disease: a systematic review and meta-analysisMeta-Analysis · 2026
3Clinical impact and cost-effectiveness of vaccinating infants and adolescents against invasive meningococcal B disease in the NetherlandsCohort Study · 2026
4Vaccination Against Serogroup B Meningococcal Disease: Current Status and Future Perspectives—A Consensus Document of the World Association for Infectious Diseases and Immunological Disorders (WAidid)Review · 2026 · 1 citations
5P-1492. Modeling the Public Health Impact of Routine Vaccination of Infants in the United States Against Invasive Meningococcal Disease Caused by Serogroup BOriginal Research · 2026